Publ3 search

Z6_60GI02O0O8IDC0QEJUJ26TJDI4

Error:

Javascript is disabled in this browser. This page requires Javascript. Modify your browser's settings to allow Javascript to execute. See your browser's documentation for specific instructions.

Publikační činnost

Probíhá načítání, čekejte prosím...

Record type:	stať ve sborníku (D)
Home Department:	Katedra interních oborů (11300)
Title:	Efficacy and Safety of Convalescent Anti-SARS-Cov-2 Plasma in COVID-19 Patients: Retrospective Chart-Review Study (RESCOVID-19)-Preliminary Results
Citace	Bohonek, M., Rezac, D., Holub, M., Jakubec, P., Kutac, D., Vabrousek, P., Chrdle, A., Hebikova, K., Sagan, J., Máca, J., Blahutová, Š., Rychlik, I., Vonaskova, K., Majercin, R., Kralova, R. a Stepanek, P. Efficacy and Safety of Convalescent Anti-SARS-Cov-2 Plasma in COVID-19 Patients: Retrospective Chart-Review Study (RESCOVID-19)-Preliminary Results. In: Transfusion Supplement Article 2022-11-01 Orlando. Association for the Advancement of Blood & Biotherapies, 2022. s. 92-92. ISSN 0041-1132.

Subtitle
Publication year:	2022
Obor:
Number of pages:	1
Page from:	92
Page to:	92
Form of publication:	Elektronická verze
ISBN code:	neuvedeno
ISSN code:	0041-1132
Proceedings title:	Transfusion Supplement Article
Proceedings:	Mezinárodní
Publisher name:	Association for the Advancement of Blood & Biotherapies
Place of publishing:	neuvedeno
Country of Publication:	Sborník vydaný v zahraničí
Název konference:
Conference venue:	Orlando
Datum zahájení konference:
Typ akce podle státní příslušnosti účastníků:	Celosvětová akce
WoS code:
EID:

Key words in English:	SARS-CoV-2, antibodies, COVID-19, convalescent plasma
Annotation in original language:	We carried out retrospective multicentric study in patients with COVID-19 treated with convalescent anti-SARS-CoV-2 plasma (CP) for efficacy and safety evaluation of such treatment on clinical sites in the Czech Republic. The primary objective was the efficacy of treatment in patients treated with CP compared to standard of care (SoC) in correlation to disease severity independent of the duration of symptoms. The secondary objective was the efficacy of treatment with CP compared to SoC in correlation to disease severity irrespective of virus-neutralizing titer ≥1:80 or equivalent anti-SARS-CoV-2 antibody levels.
Annotation in english language:

References

Reference

R01:

Complementary Content

${loading}